A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
A Prospective Study of Constructing Immune Repertoire Using Next-generation Sequencing (NGS) to Monitor the Therapeutic Effect in NSCLC Patients
Sponsor: Geneplus-Beijing Co. Ltd.
Listed as NCT03373955, this observational or N/A phase trial focuses on Non-small Cell Lung Cancer and remains ongoing. Sponsored by Geneplus-Beijing Co. Ltd., it has been updated 13 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Apr 2023 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Dec 2021 — Apr 2023 [monthly]
Recruiting
-
Apr 2021 — Dec 2021 [monthly]
Recruiting
Status: Unknown Status → Recruiting
▶ Show 8 earlier versions
-
Feb 2021 — Apr 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Feb 2019 — Nov 2020 [monthly]
Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Geneplus-Beijing Co. Ltd.
- Sichuan University
For direct contact, visit the study record on ClinicalTrials.gov .